HCV - HGS Signs Amgen, PDL For Partners In Non-Core Assets

HGS Signs Amgen, PDL For Partners In Non-Core Assets
BioWorld Online (subscription), GA - Jan 10, 2006... Also, the company expects to start Phase III development of Albuferon (albumin-interferon alpha 2b) for chronic hepatitis C by the end of 2006, assuming ...

Hepatitis C Patients Taxing Medical System
Forbes - Dec 30, 2005About 3 million people in the United States have chronic hepatitis C virus (HCV), and many of them contracted it in the 1970s, before testing and safe needle ...

Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ...
PR Newswire (press release), NY - Jan 4, 2006... recombinant interferon-alpha 2-b), for the treatment of malignant melanoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, chronic hepatitis C and chronic ...

Organ Donor Rates for 2005 Worst Ever.
Scoop.co.nz (press release), New Zealand - Jan 10, 2006... expected to double over the next decade, requiring more donors due the expected doubling of end stage liver disease from chronic hepatitis C. (Currently there ...

Peregrine accelerates Tarvacin development
Pharmaceutical Business Review - Jan 19, 2006... biopharm company Peregrine Pharmaceuticals has accelerated its clinical program for Tarvacin, an anti-viral designed to treat chronic hepatitis C, expecting to ...